Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tragara Pharmaceuticals, Inc.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Females with pathologically determined locally advanced or metastatic human epidermal growth factor receptor 2 positive (HER2/neu+) breast cancer
Have progressed after treatment with chemotherapy including a taxane and trastuzumab
Must have measurable disease by RECIST
ECOG PS of 0,1, or 2
MUGA scan or echocardiogram results show left ventricular ejection fraction greater than or equal to 50%
You may not be if
Radiation therapy within 2 weeks, chemotherapy within 3 weeks, or noncytoxic investigational agents within 4 weeks of initiating study treatment
Evidence of New York Heart Association class III or greater cardiac disease
History of MI, stroke, ventricular arrhythmia, or symptomatic conduction abnormality
History of congenital QT prolongation
Concurrent severe or uncontrolled medical disease
Symptomatic central nervous system metastases
Pregnant or nursing women
Hypersensitivity or intolerance to apricoxib, lapatinib, capecitabine, 5-FU, sulfonamides, aspirin, or NSAIDs
Severe renal insufficiency
History of upper GI bleeding, ulceration, or perforation- Concurrent use of potent CYP3A4 inhibitors and CYP3A4 inducers
Prior treatment with capecitabine
Patients on anti-arrhythmic treatment
Prior lapatinib therapy
Clareo Health | APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)
